Tirzepatide 5mg
Tirzepatide 5mg is a prescriber-directed weight-management medication option. It should be used as part of a broader care plan that includes nutrition, activity, contraindication screening, and monitoring.
Tirzepatide 5 mg is a compounded subcutaneous injectable preparation of tirzepatide, a dual GIP and GLP-1 receptor co-agonist. The 5 mg dose corresponds to the first maintenance dose in the standard titration schedule for type 2 diabetes mellitus and chronic weight management. Genesis Compounding prepares this as a prescription-only, patient-specific 503A compounded preparation and it is not FDA-approved as a compounded product.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Tirzepatide 5 mg | Dual GIP/GLP-1 receptor co-agonist providing glucose-dependent insulin secretion enhancement, glucagon suppression, gastric-emptying delay, and appetite reduction for glycemic control and weight loss. |
Administered by subcutaneous injection once weekly into the abdomen, thigh, or upper arm. Rotate injection sites each week. Inspect solution before use (clear, colorless to slightly yellow); discard if discolored or particulate.
Tirzepatide 5 mg once weekly is typically reached after 4 weeks on the 2.5 mg initiation dose. It may serve as a maintenance dose or a step in ongoing titration:
- May be increased to 7.5 mg after at least 4 weeks on 5 mg if additional glycemic or weight response is needed
- Maximum dose: 15 mg once weekly
- All titration decisions are made by the prescribing clinician
- Tirzepatide: Co-agonist at GIP and GLP-1 receptors. GLP-1 receptor activation stimulates glucose-dependent insulin release, suppresses glucagon, delays gastric emptying, and decreases appetite via hypothalamic signaling. GIP receptor activation amplifies insulin secretion and may modulate adipocyte metabolism. The dual mechanism drives complementary glucose lowering and weight reduction.
Tirzepatide 5 mg is used for type 2 diabetes mellitus and as part of a chronic weight management program in adults with obesity or overweight with weight-related comorbidities. Clinical considerations are consistent across all tirzepatide doses: monitor for GI tolerability, glycemic response, pancreatitis, and thyroid-related signs.
Contraindications:
- Personal or family history of MTC or MEN 2
- Hypersensitivity to tirzepatide
Warnings & Precautions:
- Thyroid C-cell tumor risk (rodent signal; clinical significance unknown)
- Pancreatitis: discontinue if suspected
- Hypoglycemia with concurrent insulin/sulfonylurea
- GI adverse effects, particularly during escalation
- Dehydration and acute kidney injury
Drug Interactions:
- Insulin/secretagogues: hypoglycemia risk
- Oral medications: delayed gastric emptying may alter absorption kinetics
Common Side Effects: Nausea, vomiting, diarrhea, constipation, decreased appetite, and injection site reactions.
Refrigerate at 2–8°C; protect from light; do not freeze. Use within the beyond-use date specified by Genesis Compounding.
Is 5 mg the first therapeutic dose of tirzepatide?
Yes. Per the standard titration schedule, 2.5 mg is for treatment initiation only (not intended for glycemic control), and 5 mg is the first dose with therapeutic intent, typically reached after 4 weeks on 2.5 mg.
How is this injected?
Subcutaneous injection once weekly. Rotate sites among abdomen, thigh, and upper arm.
Is this FDA-approved?
Commercial tirzepatide 5 mg is available in FDA-approved products (Mounjaro, Zepbound). This is a 503A compounded preparation by Genesis Compounding and is not FDA-approved as a compounded product.
How long before I notice effects on blood sugar or weight?
Measurable glycemic improvements may be seen within 4–8 weeks. Meaningful weight loss typically becomes apparent over 12–16 weeks, with maximum effects at higher maintenance doses after several months.
What if I have a history of pancreatitis?
Tirzepatide has not been studied in patients with a history of pancreatitis. Discuss your medical history with your prescriber before initiating therapy.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.